Patents by Inventor Samuel R. Denmeade

Samuel R. Denmeade has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10967046
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: April 6, 2021
    Assignee: The Johns Hopkins University
    Inventors: John T. Isaacs, Samuel R. Denmeade, W. Nathaniel Brennen
  • Publication number: 20200268836
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.
    Type: Application
    Filed: March 11, 2020
    Publication date: August 27, 2020
    Inventors: John T. Isaacs, Samuel R. Denmeade, W. Nathaniel Brennen
  • Publication number: 20200170960
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Application
    Filed: July 8, 2019
    Publication date: June 4, 2020
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Patent number: 10596226
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: March 24, 2020
    Assignee: The Johns Hopkins University
    Inventors: John T. Isaacs, Samuel R. Denmeade, W. Nathaniel Brennen
  • Patent number: 10369113
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 6, 2019
    Assignee: The Johns Hopkins University
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Publication number: 20180148480
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for using synthetically enhanced T-cells to treat cancer. The present invention also provides a T-cell engineered (a) to express at least one CAR that binds tumor antigens; and (b) to inducibly express a prostate-specific antigen (PSA)-activated pro-aerolysin (PA) upon tumor antigen recognition by CAR.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 31, 2018
    Inventors: John T. Isaacs, Samuel R. Denmeade, Nathaniel E. Brennen
  • Publication number: 20180008668
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.
    Type: Application
    Filed: January 15, 2016
    Publication date: January 11, 2018
    Inventors: John T. Isaacs, Samuel R. Denmeade, Nathaniel E. Brennen
  • Publication number: 20170135961
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Application
    Filed: July 13, 2016
    Publication date: May 18, 2017
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Patent number: 9422234
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: August 23, 2016
    Assignee: The Johns Hopkins University
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Patent number: 8957016
    Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: February 17, 2015
    Inventors: Samuel R. Denmeade, John T. Isaacs
  • Patent number: 8822406
    Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: September 2, 2014
    Assignee: GenSpera, Inc.
    Inventors: Samuel R. Denmeade, John T. Isaacs
  • Publication number: 20140087991
    Abstract: Provided herein are a novel class of oligopeptides and prodrugs that include amino acid sequences containing cleavage sites for fibroblast activation protein (FAP). Also provided herein are methods of treating FAP related disorders, including cancer.
    Type: Application
    Filed: August 22, 2013
    Publication date: March 27, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Samuel R. Denmeade, Saurabh Aggarwal
  • Patent number: 8669231
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 11, 2014
    Assignee: GenSpera, Inc.
    Inventors: Samuel R. Denmeade, John Tod Isaacs, Hans Lilja
  • Patent number: 8450280
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: May 28, 2013
    Assignee: GenbSpera, Inc.
    Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
  • Publication number: 20120309692
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Application
    Filed: May 16, 2012
    Publication date: December 6, 2012
    Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
  • Publication number: 20120283166
    Abstract: Provided herein are a novel class of oligopeptides and prodrugs that include amino acid sequences containing cleavage sites for fibroblast activation protein (FAP). Also provided herein are methods of treating FAP related disorders, including cancer.
    Type: Application
    Filed: May 14, 2012
    Publication date: November 8, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Samuel R. Denmeade, Saurabh Aggarwal
  • Publication number: 20120270767
    Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.
    Type: Application
    Filed: May 31, 2012
    Publication date: October 25, 2012
    Inventors: Samuel R. Denmeade, John T. Isaacs
  • Publication number: 20120270768
    Abstract: The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the thug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.
    Type: Application
    Filed: May 31, 2012
    Publication date: October 25, 2012
    Inventors: Samuel R. Denmeade, John T. Isaacs
  • Patent number: 8258256
    Abstract: The instant invention provides methods and compositions for the treatment and diagnosis of cancer, e.g., cancers characterized by the expression of prostate specific membrane antigen (PSMA).
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: September 4, 2012
    Assignee: The Johns Hopkins University
    Inventors: Samuel R. Denmeade, Saurabh Aggarwal
  • Publication number: 20110245147
    Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Application
    Filed: January 10, 2011
    Publication date: October 6, 2011
    Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja